ClinicalTrials.gg

Neurodevelopmental Disorders clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 353 studies for Neurodevelopmental Disorders across more than 10 countries. 142 are recruiting or about to start. 153 of them are mainly about Neurodevelopmental Disorders (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 38 narrower conditions too, such as Attention Deficit Disorder with Hyperactivity: 7,109 studies, 1,649 open.

Status

Completed
145
Recruiting
100
Not yet recruiting
32
Active, not recruiting
30
Status unknown
29
Enrolling by invitation
10

Phase

Phase 3
17
Phase 2
14
Phase 1
6
Phase 4
3
Early Phase 1
2

Where

United States
99
France
50
Italy
35
Canada
25
Spain
20
United Kingdom
18

Who develops what

Add Neurodevelopmental Disorders to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 5 programs from 5 companies, 2 with this as their studies’ main aim; 2 with a live phase 3 study; 4 primary completions in the next 12 months. Compare H. Lundbeck and Shionogi here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 5 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 31 Dec 2026 est.bexicaserin · H. Lundbeck A/S · Phase 3 registry mapping onlyNCT06660394 A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) — primary endpoint: Frequency Percent Change in Countable Motor Seizures During Treatment Compared to Baseline · 108 enrolled
  • May 2027 est.radiprodil · GRIN Therapeutics, Inc. · Phase 3 main aimNCT07224581 Beeline: A Phase 3 Study in GRIN-related Neurodevelopmental Disorder — primary endpoint: Part A - Phase 3 Cohort 1 (Qualifying Seizures Cohort): Countable motor seizures (CMS) · 100 enrolled
  • May 2027 est.CTH120 · Connecta Therapeutics, S.L. · Phase 2 named, not the main aimNCT07654114 Safety, Tolerability, and Preliminary Effectiveness of CTH120 in Fragile X Syndrome — primary endpoint: Treatment-emergent adverse events (TEAEs). · 30 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Neurodevelopmental Disorders studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

50studies finish main data collection within a year4 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 100 Neurodevelopmental Disorders studies recruiting now, 20 (20%) set no upper age limit and 76 (76%) stop at 75 or younger. 86 (86%) take children under 18. 5 (5%) are for women only and 1 (1%) for men only; 31 (31%) take healthy volunteers.

Recruiting studies that take each age, of 100
AgeWomenMen
1056 (56%)55 (55%)
1844 (44%)40 (40%)
3039 (39%)35 (35%)
4036 (36%)33 (33%)
5029 (29%)28 (28%)
6525 (25%)24 (24%)
7524 (24%)23 (23%)
8523 (23%)22 (22%)

Across all 353 studies, recruiting or not: 79% stop at 75 or younger and 79% at 65; 86% take children; 5% are for women only and 1% for men only; 37% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Neurodevelopmental Disorders studies take

Of 148 interventional studies with no phase under Neurodevelopmental Disorders, half reached primary completion within 30 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Interventional, no phase30 mo15–52 · 148 studies—30 mo15–52 · 142 studies
Observational59 mo32–101 · 70 studies—59 mo32–101 · 67 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 353. Browse all 353 → or search them.